Drug Combination Details
| General Information of the Combination (ID: C15069) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Celecoxib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| In-vivo Model | Mammary carcinogenesis was initiated with two intra peritoneal doses (50 mg/kg body weight each) of N-methyl-N-nitrosourea (NMU) dissolved in a physiological NaCl solution. | |||||
| Experimental
Result(s) |
Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. Eur J Cancer Prev. 2014 Nov;23(6):506-13. | |||